Industry-Supported Symposium

Limb-Girdle Muscular Dystrophies: Clinical Course of Disease and Advances in Gene Therapy Development

Supported by

This program aims to review the current understanding and unmet needs of limb-girdle muscular dystrophies (LGMDs) as well as explore the rationale and clinical data for an investigational gene therapy for a particular LGMD subtype, LGMD2E/R4.

Agenda

• Welcome & Introductions
• The Clinical Course: Understanding LGMD Disease State and Unmet Needs
• Evolving the Approach: Investigational SRP-9003 for LGMD2E/R4
• Q&A

Speakers

• Dr. med. André Müller-York, Senior Director, LGMD Medical Lead, Global Medical Affairs, Sarepta Therapeutics, Inc.
• Jesantha Coy, B.Pharm, Executive Director, Global Program Team Leader, Sarepta Therapeutics, Inc.